SHERIDAN, WYOMING - April 14, 2026 - Illumina has announced the acquisition of SomaLogic, describing the deal as a unification that will deliver a powerful portfolio of proteomics solutions. The move extends Illumina's core sequencing and array business into protein-level biology, a domain increasingly central to translational research, drug discovery, and clinical diagnostics. Combined with Illumina's existing NGS-based proteomics services offered through the Illumina Protein Prep solution, the acquisition adds significant depth to the company's multiomics ambitions. For laboratory operators and life science research institutions, the deal raises the prospect of sourcing genomic and proteomic workflows from a single integrated vendor.
Business Impact
The SomaLogic acquisition positions Illumina to offer end-to-end multiomics workflows under a consolidated platform, reducing the need for research institutions and clinical labs to procure proteomics capabilities from separate vendors. Illumina already provides NGS-based proteomics services through the Illumina Protein Prep solution via trusted service providers, and the addition of SomaLogic's assets is expected to expand that offering materially. For biopharma companies, academic research centers, and clinical diagnostics operators, a single-vendor multiomics stack lowers integration friction and may simplify data interoperability and procurement. The deal is structured as an acquisition, and Illumina characterizes the outcome as a "powerful portfolio of proteomics solutions" available to its customer base.
Portfolio and Platform Context
Illumina's existing product ecosystem spans sequencing platforms - including the NovaSeq X and the NextSeq 1000 and 2000 series - library preparation kits, microarray scanners, and cloud-based informatics tools such as Illumina Connected Multiomics and BaseSpace Sequence Hub. The company has also added single-cell RNA sequencing with PIPseq chemistry to its workflow portfolio, offering cell-level resolution across multiple biological layers. The NovaSeq X innovation roadmap, which Illumina positions as built to accelerate performance and value, is expected to serve as a backbone instrument for high-throughput multiomics applications as proteomics integration advances. An updated NGS Workflow Finder - recently expanded to include oncology workflows - provides a practical planning tool for labs mapping out sequencing and, prospectively, proteomics workflows.
Operational Considerations
Laboratory operators and capital procurement decision-makers will be watching the integration timeline for SomaLogic's platform into Illumina's connected analytics infrastructure. Illumina offers reagent rental solutions and broader financial solutions alongside instrument purchases, which could ease deployment for labs adding proteomics capacity without large upfront capital commitments. Clinical research users in oncology, rare disease genomics, and reproductive health represent addressable early segments, given existing product lines including TruSight Oncology and related genetic disease assays. The company's Clarity LIMS and Illumina Connected Analytics tools are likely integration points as proteomics data becomes part of combined workflows.
Sector Context
The proteomics tools market has attracted growing investment as the limitations of genomics-only approaches in drug target identification and disease characterization have become more apparent. Protein-level data provides functional insight that DNA sequence data alone cannot reliably deliver, making proteomics an increasingly recognized component of complex disease research and precision medicine pipelines. Illumina's acquisition of SomaLogic reflects a broader pattern of consolidation in the life sciences tools sector, where platform breadth and data integration capability are becoming primary competitive differentiators. The deal also extends Illumina's stated corporate objective to accelerate access to genomics - now effectively broadened to encompass proteomics - across research and clinical settings globally.
Key facts:
- Illumina has acquired SomaLogic, with the stated outcome being "a powerful portfolio of proteomics solutions"
- Illumina already offers NGS-based proteomics services through the Illumina Protein Prep solution via service providers
- The company's platform includes NovaSeq X, NextSeq 1000 and 2000 systems, Illumina Connected Multiomics, and BaseSpace Sequence Hub
- Single-cell RNA sequencing with PIPseq chemistry has been added to Illumina's workflow portfolio
- The NGS Workflow Finder has been updated to include oncology workflows